7 citations
,
June 2007 in “AIDS” A man's hair loss was linked to his HIV medication, which improved after changing drugs.
8 citations
,
August 2022 in “Microorganisms” A standardized drug development platform is essential for efficient and effective drug repurposing, especially during pandemics.
235 citations
,
June 2021 in “International Journal of Molecular Medicine” Kidney stones form due to factors like urine concentration, calcium deposits, hormones, gut bacteria, and immune response.
21 citations
,
March 2018 in “Experimental Dermatology” The guide explains how to study human skin fat cells and their tissue, aiming to improve research and medical treatments.
5 citations
,
June 2019 in “Open Forum Infectious Diseases” Six African American women experienced hair loss after switching to a new HIV medication.
1 citations
,
June 2025 in “Frontiers in Pediatrics” Early detection and infection prevention are crucial for improving survival in pediatric lupus patients with aplastic anemia.
1 citations
,
November 2011 in “Journal of AIDS & Clinical Research” Raltegravir may cause hair loss in some patients.
September 2020 in “arXiv (Cornell University)” Some existing drugs and natural products might work against COVID-19 by targeting the virus's main protease.
January 2019 in “Springer eBooks” Some chemicals and drugs can cause hair loss, which usually grows back after stopping the treatment.
1 citations
,
December 2018 in “IntechOpen eBooks” Human hair shows promise for non-invasive medical testing, but more research is needed to standardize its use.
111 citations
,
February 2017 in “Antiviral research” Researchers found several compounds that could potentially treat Zika virus.
5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
2 citations
,
November 2011 in “Journal of Infection” A woman with asthma improved from a severe fungal infection after treatment change, and most HIV-positive women in a UK study had low immune cell counts but were responding well to treatment.
9 citations
,
June 2022 in “Microorganisms” We need safe, affordable drugs to fight coronaviruses effectively.
350 citations
,
June 1989 in “The American Journal of Medicine” Itraconazole is potentially effective for treating invasive aspergillosis, but more research is needed.
100 citations
,
November 2021 in “Cell Research” Cepharanthine and Trifluoperazine are effective against SARS-CoV-2.
5 citations
,
December 2022 in “Annals Academy of Medicine Singapore” Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
5 citations
,
July 2007 in “PubMed” An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.
87 citations
,
March 2013 in “Expert Review of Anticancer Therapy” Afatinib often causes skin problems that need proactive management.
13 citations
,
July 2019 in “Toxicology research” Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.
2 citations
,
July 2019 in “PLOS ONE” Certain genetic variations are linked to higher liver enzyme levels in patients treated for chronic hepatitis C with specific drugs.
2 citations
,
November 2025 in “Pharmacology Research & Perspectives” Avacopan may cause unexpected side effects, so early monitoring is important.
1 citations
,
April 2025 in “Tropical Journal of Natural Product Research” Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
20 citations
,
August 2008 in “Journal of Medical Case Reports” Ondansetron can cause serious allergic reactions, so use it carefully.
1 citations
,
October 2025 in “Frontiers in Immunology” Avacopan is generally safe, with some minor side effects like nausea and fatigue.
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
50 citations
,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
3 citations
,
September 2020 in “Molecular Brain” The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
1 citations
,
May 2021 in “Journal of the Endocrine Society” A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.